AcquisitionOther
AVENUE THERAPEUTICS, INC. acquired Baergic Bio, Inc
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
AVENUE THERAPEUTICS, INC. -> Baergic Bio, Inc
Its pipeline currently includes a single compound, BAER-101, an oral small molecule selective GABA-A α2/3 receptor positive allosteric modulator, which was in-licensed from AstraZeneca Plc.
Open source record (SEC) ↗